Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to 12.99%.

  • Aytu Biopharma's EBITDA Margin fell 25400.0% to 12.99% in Q4 2025 from the same period last year, while for Dec 2025 it was 13.85%, marking a year-over-year decrease of 23200.0%. This contributed to the annual value of 11.79% for FY2025, which is 84500.0% down from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's EBITDA Margin is 12.99%, which was down 25400.0% from 10.83% recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's EBITDA Margin peaked at 16.78% during Q4 2023, and registered a low of 220.76% during Q1 2022.
  • Over the past 5 years, Aytu Biopharma's median EBITDA Margin value was 16.3% (recorded in 2025), while the average stood at 45.83%.
  • As far as peak fluctuations go, Aytu Biopharma's EBITDA Margin crashed by -1315900bps in 2021, and later skyrocketed by 1831100bps in 2023.
  • Over the past 5 years, Aytu Biopharma's EBITDA Margin (Quarter) stood at 48.84% in 2021, then surged by 46bps to 26.13% in 2022, then soared by 164bps to 16.78% in 2023, then plummeted by -162bps to 10.45% in 2024, then decreased by -24bps to 12.99% in 2025.
  • Its EBITDA Margin stands at 12.99% for Q4 2025, versus 10.83% for Q3 2025 and 50.37% for Q2 2025.